These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

153 related articles for article (PubMed ID: 12643016)

  • 1. Current therapies in ovarian cancer.
    Fields AL; Runowicz CD
    Cancer Invest; 2003; 21(1):148-56. PubMed ID: 12643016
    [No Abstract]   [Full Text] [Related]  

  • 2. [Gemicitabine in the treatment of epithelial ovarian cancer].
    Pautier P; Gutierrez M; Lhomme C
    Bull Cancer; 2002 Aug; 89 Spec No():S115-9. PubMed ID: 12449041
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Own experiences in salvage chemotherapy of ovarian cancer--a preliminary report].
    Gerber J; Jedryka M; Gabryś M; Goluda M
    Ginekol Pol; 2002 Nov; 73(11):1048-52. PubMed ID: 12722398
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Phase I/II study of tandem cycles of high-dose chemotherapy followed by autologous hematopoietic stem cell support in women with advanced ovarian cancer.
    Tiersten A; Selleck M; Smith DH; Wertheim I; Kaufman E; Hershman D; Vahdat LT; Savage DG; MacArthur RB; Hesdorffer C
    Int J Gynecol Cancer; 2006; 16(1):57-64. PubMed ID: 16445611
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Lack of substantial five year disease-free survival by primary aggressive surgery and cisplatin-based chemotherapy or by salvage intraperitoneal cisplatin-based chemotherapy.
    Piver MS; Baker TR; Driscoll DL
    Eur J Gynaecol Oncol; 1990; 11(4):243-50. PubMed ID: 2245807
    [No Abstract]   [Full Text] [Related]  

  • 6. Is it time for some new approaches for treating advanced ovarian cancer?
    McGuire WP
    J Natl Cancer Inst; 2006 Aug; 98(15):1024-6. PubMed ID: 16882933
    [No Abstract]   [Full Text] [Related]  

  • 7. Medical therapy of advanced malignant epithelial tumours of the ovary.
    Colombo N; Parma G; Bocciolone L; Franchi D; Sideri M; Maggioni A
    Forum (Genova); 2000; 10(4):323-32. PubMed ID: 11535983
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Progressive epithelial ovarian carcinoma. Prognostic factors and clinical management.
    Grønlund B
    Dan Med Bull; 2006 Aug; 53(3):232-57. PubMed ID: 17092448
    [No Abstract]   [Full Text] [Related]  

  • 9. Intraperitoneal therapy for advanced ovarian cancer: will it become standard care?
    Bankhead C
    J Natl Cancer Inst; 2006 Apr; 98(8):510-2. PubMed ID: 16622116
    [No Abstract]   [Full Text] [Related]  

  • 10. Intraperitoneal therapy of ovarian cancer.
    Markman M
    Semin Oncol; 1998 Jun; 25(3):356-60. PubMed ID: 9633848
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Intraperitoneal cisplatin and paclitaxel in ovarian cancer.
    Armstrong DK; Bundy B; Wenzel L; Huang HQ; Baergen R; Lele S; Copeland LJ; Walker JL; Burger RA;
    N Engl J Med; 2006 Jan; 354(1):34-43. PubMed ID: 16394300
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Intraperitoneal cisplatin therapy in ovarian cancer: comparison with standard intravenous carboplatin and paclitaxel.
    Ozols RF; Bookman MA; du Bois A; Pfisterer J; Reuss A; Young RC
    Gynecol Oncol; 2006 Oct; 103(1):1-6. PubMed ID: 16904166
    [No Abstract]   [Full Text] [Related]  

  • 13. Secondary cytoreduction in epithelial ovarian cancer.
    Morgan MA; Rubin SC
    Crit Rev Oncol Hematol; 1995 Jan; 18(1):1-8. PubMed ID: 7695822
    [No Abstract]   [Full Text] [Related]  

  • 14. Intraperitoneal therapy for ovarian cancer: why has it not become standard?
    Rowan K
    J Natl Cancer Inst; 2009 Jun; 101(11):775-7. PubMed ID: 19470952
    [No Abstract]   [Full Text] [Related]  

  • 15. Ovarian cancer: review of the National Institute for Clinical Excellence (NICE) guidance recommendations.
    Johnston SR
    Cancer Invest; 2004; 22(5):730-42. PubMed ID: 15581055
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Markov-modeling for the administration of platinum analogues and paclitaxel as first-line chemotherapy as well as topotecan and liposomal doxorubicin as second-line chemotherapy with epithelial ovarian carcinoma.
    Fedders M; Hartmann M; Schneider A; Kath R; Camara O; Oelschläger H
    J Cancer Res Clin Oncol; 2007 Sep; 133(9):619-25. PubMed ID: 17458562
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Progress in the management of gynecologic cancer: consensus summary statement.
    Cannistra SA; Bast RC; Berek JS; Bookman MA; Crum CP; DePriest PD; Garber JE; Koh WJ; Markman M; McGuire WP; Rose PG; Rowinsky EK; Rustin GJ; Skates SJ; Vasey PA; King L
    J Clin Oncol; 2003 May; 21(10 Suppl):129s-132s. PubMed ID: 12743127
    [No Abstract]   [Full Text] [Related]  

  • 18. Randomized trial of single agent paclitaxel given weekly versus every three weeks and with peroral versus intravenous steroid premedication to patients with ovarian cancer previously treated with platinum.
    Rosenberg P; Andersson H; Boman K; Ridderheim M; Sorbe B; Puistola U; Parö G
    Acta Oncol; 2002; 41(5):418-24. PubMed ID: 12442916
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Topotecan versus treosulfan, an alkylating agent, in patients with epithelial ovarian cancer and relapse within 12 months following 1st-line platinum/paclitaxel chemotherapy. A prospectively randomized phase III trial by the Arbeitsgemeinschaft Gynaekologische Onkologie Ovarian Cancer Study Group (AGO-OVAR).
    Meier W; du Bois A; Reuss A; Kuhn W; Olbricht S; Gropp M; Richter B; Lück HJ; Kimmig R; Pfisterer J
    Gynecol Oncol; 2009 Aug; 114(2):199-205. PubMed ID: 19446314
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Systematic review of first-line chemotherapy for newly diagnosed postoperative patients with stage II, III, or IV epithelial ovarian cancer.
    Covens A; Carey M; Bryson P; Verma S; Fung Kee Fung M; Johnston M
    Gynecol Oncol; 2002 Apr; 85(1):71-80. PubMed ID: 11925123
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.